• ‘No survivors’ found after explosion at Tennessee plant,…
  • Israel prepares for final hostage release as Gazans…
  • Oscar-winning actor Diane Keaton dies at 79
  • Diane Keaton, Oscar-winning actress, dies at 79

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Trump reacts to Ryan Routh verdict

admin - Latest News - September 23, 2025
admin
19 views 14 secs 0 Comments



President Donald Trump reacts to the verdict in the case of Ryan Routh, who was found guilty of attempting to assassinate him last year.



Source link

TAGS:
PREVIOUS
Unidentified drones shut down Nordic airports
NEXT
Sept. 23, 2025, 4:00 PM EDTBy Daniella Silva, Rob Wile and Nicole AcevedoAfter announcing a new $100,000 fee on H-1B visas, the Trump administration on Tuesday proposed overhauling the visa’s lottery selection process to prioritize higher-paid and higher-skilled foreign employees.The proposed policy changes could reignite the debate over the use of foreign labor by U.S. employers. The move comes as President Donald Trump has taken aim at H-1B visas, a program used widely by Big Tech and outsourcing companies to hire foreign workers, announcing Friday that companies would be required to pay a $100,000 fee with new applications submitted after Sept. 21. The administration on Tuesday targeted H-1B visa allocation, proposing a “weighted selection process” for when annual demand for the visas tops the 85,000 limit set by Congress, which it says has happened every year for more than a decade. The new process would replace the current lottery system that determines who gets to apply for those limited visa spots in favor of putting more weight on higher skilled and higher paid foreign workers, according to a proposed rule set to be published in the Federal Register on Wednesday. Under the current lottery rules, offers to apply for an H-1B visa are assigned at random. The Trump administration’s proposal would assign prospective employees to four different wage bands, with workers in the highest wage category being entered into the selection pool four times and those in the lowest wage category being entered into the selection pool once. The Department of Homeland Security stated in the proposal that the weighted system would better serve the visa program’s original intent and “incentivize employers to offer higher wages or higher skilled positions to H-1B workers and disincentivize the existing widespread use of the H-1B program to fill lower paid or lower skilled positions.”It said the proposed selection process would still maintain opportunities for employers to hire H-1B workers at “all wage levels.” ‘A strong signal’The H-1B visa program allows U.S. employers to temporarily hire skilled foreign workers in “specialty occupations” across health care, tech and finance industries, and other STEM-related fields.The two new proposed policies together send “a strong signal of the direction that the administration wants to go,” said Xiao Wang, CEO of Boundless Immigration, a company that offers services to people navigating the immigration process in the U.S.If adopted, the policies would benefit companies seeking to keep foreigners with specialized skills who studied at American universities in the U.S., as well as ensuring H-1B visas “disproportionately go to people who are deemed higher skilled, represented by higher wages and higher salary,” he said.Trump stated Friday that changes were needed in the visa system, saying it was designed to bring in temporary workers with “additive, high-skilled functions, but it has been deliberately exploited to replace, rather than supplement, American workers with lower-paid, lower-skilled labor.”For the last H-1B lottery round, which closed its registration in March, about 339,000 people applied. Of those, 120,141 applications were selected for the lottery, according to USCIS data.The proposal faces a 30-day public comment period before it is considered by the administration for a final rule, a process that could take months.If the changes are adopted, companies seeking to hire lower-wage workers from India and China for computer-related jobs appear likely to be among the most affected. For more than a decade, about 60% of H-1B workers approved every year have held computer-related jobs, according to Pew Research.Start-ups and smaller companies who cannot afford to pay their workers in the higher pay categories compared to major tech companies would also be impacted, Wang said.Deedy Das, a partner at Menlo Ventures venture capital group, said in a social media post that the latest proposal would hurt many tech companies.“Overall, it’s really bad for startups, early employees, helps IT consulting shops and can be easily gamed,“ Das wrote.Trump’s announcement of a new $100,000 fee on H-1B visas touched off a frenzy among current visa holders, the companies that employ them and countries around the world as they worked to understand the edict.Eventually, the White House clarified that it would be a one-time fee and apply only to new visa applicants. Trump said companies would have to pay the fee for new H-1B visa applications submitted after Sept. 21. That’s a steep rise from current fees, which are usually $2,000 to about $5,000.Both the fee and Tuesday’s proposal are likely to face challenges in court. A growing chorus on both the left and the right say an over-reliance on the visa by U.S. firms has put U.S.-born workers at a disadvantage. Commerce Secretary Howard Lutnick has called the H-1B visa program a “scam,” while the left-leaning Economic Policy Institute has claimed that some of the companies most reliant on H-1B visas, such as Amazon and Facebook’s parent, Meta, have also had sizable layoffs, though it did not cite evidence that the use of the visa and the layoffs are related.In the first half of 2025, Amazon received approval for more than 12,000 H-1B visas, while Meta received more than 5,000. Representatives for both companies did not immediately respond to requests for comment. Daniella SilvaDaniella Silva is a national reporter for NBC News, focusing on immigration and education.Rob WileRob Wile is a Pulitzer Prize-winning journalist covering breaking business stories for NBCNews.com.Nicole AcevedoNicole Acevedo is a national reporter for NBC News and NBC Latino.
Related Post
September 30, 2025
37+ actually good early October Prime Day deals
September 28, 2025
Sept. 28, 2025, 5:00 AM EDTBy Berkeley Lovelace Jr.Last winter, Brian Noonan read online that some doctors were prescribing an obscure drug, typically given to cancer patients, for autism. Curious, he looked into it for his son Benjamin, who had just been diagnosed with autism in October.“We jumped on it,” Noonan said. “It felt right and it made sense.”The medication was leucovorin, also called folinic acid. It’s a synthetic form of vitamin B9 or folate, which the body needs to make healthy blood cells. During pregnancy, folate is important to reduce the risk of birth defects.Last Monday, the drug was thrust into the national spotlight by President Donald Trump in a rambling press conference about autism that mainly focused on the president and Health Secretary Robert F. Kennedy’s claim that taking acetaminophen during pregnancy could cause autism. Trump briefly mentioned that an “existing drug” — referring to leucovorin — may help with certain symptoms of autism. For those in the autism community, leucovorin is not new. Dr. Richard Frye, a behavioral child neurologist in Phoenix has studied leucovorin and autism for two decades. He made clear that it is not a cure for autism and that more research is needed. He does, however, prescribe it to some people with autism.Noonan’s son Benjamin, who is 4 years old, is one of Frye’s patients. “He’s higher functioning,” Noonan said. “He’s verbal, but he really struggled to put together sentences.” Since starting on the medicine, the family believes Benjamin’s speech has improved, though he still has difficulties with hyperactivity and impulsiveness.Still, Noonan added, he’s under no impression that the drug is a miracle pill. Benjamin also attends a behavioral program preparing him for kindergarten, Noonan said, and he plans to enroll him in speech and occupational therapy. “We very, very much understand we’re still taking an experimental medication,” he said. The Noonan family. Benjamin, 4, who has autism, has used leucovorin.Courtesy of Brian NoonanOther families say the drug conferred larger benefits.Ben Blomgren, of Minneapolis, said his 11-year-old son, Josh, had been prescribed leucovorin off-label in February after he was at risk of being kicked out of school, even as they tried behavioral modification methods.“He’s pretty severe,” Blomgren said. “He didn’t have any language skills. He was not toilet trained.” After starting the medication, Blomgren said Josh’s sleep improved, he’s fully toilet trained and he’s stopped running away from them. “It wasn’t overnight, but we saw major improvement,” he said. Yomarie Miranda, of Florida, said she saw improvements in her 7-year-old son Ethan after he started the medication, including following instructions in class.Ethan was prescribed the medication off label earlier this month, she said.“He’s now looking at me when I speak with him. He’s talking more than before with complete sentences,” she said.A highly unusual moveThe Food and Drug Administration first approved leucovorin in the 1980s to help reduce the toxic side effects of certain chemotherapy drugs.In the decades since, researchers have also studied whether it might treat cerebral folate deficiency (CFD), a neurological condition that makes it harder for folate to reach the brain. Some children with autism also have cerebral folate deficiency, which neurologists say can affect speech, mood and behavior. Last Monday, the FDA said it planned to update the drug’s label to include that use.But the agency’s decision, experts say, rests on just a handful of small studies. And despite Trump’s endorsement, the maker of the brand-name version, GSK, has yet to submit an application to the agency to change the label. In a statement, GSK said it will be submitting the request to expand the approval to include cerebral folate deficiency, though the statement does not mention autism. (Because leucovorin is already an FDA-approved drug, doctors have been able to prescribe it “off label” for other uses, though insurance may not cover it.) It’s a highly unusual move for the FDA: pushing a drug for chemotherapy side effects as a therapy for autism without a formal submission and limited evidence.“It’s incredibly irresponsible,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. “For 60-plus years, we’ve counted on the FDA to help patients distinguish between products that work and products that don’t work. And here we saw the FDA making an announcement relying on a summary of unclear data and announcing that they had already decided to approve it.”Alycia Halladay, chief science officer at the nonprofit Autism Science Foundation, was frustrated by the implication that this is a breakthrough in autism research.“It’s not like scientists have just been staring at their belly buttons for 20 years, not looking at autism treatments,” Halladay said in an interview earlier this week. “They have, but the standards have been very high to get [treatments] approved.”Andrew Nixon, a spokesperson for the Department of Health and Human Services, which oversees the FDA, said in a statement: “Analysis across 23 publications from 2009-2024 demonstrated the effectiveness for CFD. Overall, 85% of patients experienced some type of clinical benefit including improved speech/communication capabilities.” Nixon’s statement did not mention autism, and he did not respond to follow-up questions.David Mandell, a psychiatry professor at the University of Pennsylvania, said HHS’ claim that 85% of patients experienced a benefit is a “quite a conceptual leap” because it assumes people with cerebral folate deficiency also have autism.Cerebral folate deficiency “is an extremely rare event, and it is accompanied by symptoms of epilepsy, really severe neurodevelopmental problems and some of those symptoms can look like autism, but it’s not,” he said.“I could not think of a single FDA approval that has such weak evidence in the past 20 years,” Mandell added.Frye, the Phoenix neurologist, estimates up to three-quarters of autistic children have antibodies linked to cerebral folate deficiency, based on his research. Other estimates are much lower: Alycia Halladay, chief science officer at the nonprofit Autism Science Foundation, put the rates at roughly 10% to 30%.The studies on leucovorin are small but look interesting, said Dr. Scott Gottlieb, a former FDA commissioner.“It certainly merits follow up,” Gottlieb said.One of the studies was conducted by Frye: a placebo-controlled trial of more than 40 children with the antibodies, published in Molecular Psychiatry in 2018. It found around two-thirds of kids who got the drug saw improvements in verbal communication after 12 weeks. Others saw no changes. The children all had language impairments, as well as a common type of autism that’s not linked to other neurological diseases.Mandell, however, said the results shouldn’t be taken as evidence.“They claim that in certain subgroups of kids in their already small sample, they find these very large effects,” he said, adding that larger-scale trials that establish clear outcomes ahead of time are needed to verify the results. Kesselheim said it’s important for patients to have access to medications that could have a benefit, especially when there is an unmet medical need. But, he said, there are still a number of unanswered questions.“There is no accurate testing for this,” he said. “What are low folate levels? What are normal folate levels? All of that stuff should be worked out.”Frye said he currently uses two methods to assess whether a child has a folate deficiency: a spinal tap — also known as a lumbar puncture — which involves inserting a needle into the lower back to collect fluid from the spinal cord, and a folate receptor antibody test originally developed for pregnant women that isn’t approved by the FDA for diagnosing folate deficiency in children. Edward Quadros, a research professor at SUNY Downstate Health Sciences University who has worked with Frye studying leucovorin for autism, said parents are already trying the drug, including supplement versions, which aren’t regulated and can be dangerous.“By making the FDA approve it, and reputable pharmaceutical companies manufacturing it and selling it, at least it gives you quality dosing,” Quadros said.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.Aria Bendix contributed.
September 22, 2025
Musk sits with Trump at Kirk memorial
September 24, 2025
Is leucovorin an effective treatment for autism? Here's what research shows
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved